Dexmedetomidine is used to sedate patients who are on mechanical ventilation in intensive care units, and to provide sedation during medical procedures. It helps keep patients calm and reduces anxiety while allowing them to be easily awakened.[2] Precedex is currently approved and in use across 168 indications[4].[1]
Precedex is one of 1622 small molecule programs targeting Alcohol Withdrawal. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
348 competitors in Prostate Cancer
Precedex
Paraplatin
Rubraca
Alinamin
Zejula
Aglatimagene Besadenovec
Docetaxel /m²
PSMA-1007
INR101
Trexall
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Dexmedetomidine
NCT06639659
Sedation
NCT07166666
Functional Endoscopic Sinus Surgery
NCT07213037
Extracorporeal Membrane Oxygenation
NCT03593408
Dexmedetomidine
NCT07271147
Dexmedetomidine
NCT07214701
Clinical
Regulatory
Dec 17, 1999
PRECEDEX
NDA NDA021038
May 8, 2001
PRECEDEX
NDA NDA021038
Oct 17, 2008
PRECEDEX
NDA NDA021038
Oct 13, 2010
PRECEDEX
NDA NDA021038
Mar 13, 2013
PRECEDEX
NDA NDA021038
Jun 17, 2013
PRECEDEX
NDA NDA021038
Jun 17, 2013
PRECEDEX
NDA NDA021038
Sep 28, 2013
PRECEDEX
NDA NDA021038
Jan 16, 2014
PRECEDEX
NDA NDA021038
Apr 18, 2014
PRECEDEX
NDA NDA021038
Nov 14, 2014
PRECEDEX
NDA NDA021038
Nov 14, 2014
PRECEDEX
NDA NDA021038
Nov 14, 2014
PRECEDEX
NDA NDA021038
Oct 21, 2015
DEXMEDETOMIDINE HYDROCHLORIDE
NDA NDA206628
Apr 11, 2016
PRECEDEX
NDA NDA021038
Jan 31, 2020
PRECEDEX
NDA NDA021038
Jan 31, 2020
PRECEDEX
NDA NDA021038
Apr 5, 2022
IGALMI
NDA NDA215390
Aug 12, 2022
PRECEDEX
NDA NDA021038
Aug 12, 2022
PRECEDEX
NDA NDA021038
Dec 16, 2022
PRECEDEX
NDA NDA021038
Oct 11, 2024
PRECEDEX
NDA NDA021038
May 1, 2026
PRECEDEX
NDA NDA021038
Sources
Details
Patent Cliff
Jan 4, 2032
Earliest patent expiration — generic entry possible after this date